Acquired immuno-deficiency syndrome (AIDS) is a major pandemic caused by human immuno-deficiency virus (HIV) and considerable efforts are being completed for years to build up drugs against the outrageous disease. The HIV genome encodes for the protease, reverse transcriptase and integrase enzymes. Combination antiviral therapy with protease and reverse transcriptase inhibitors has established the potential therapeutic usefulness of antiviral therapy for treatment for AIDS. 1) However, the capability of HIV to rapidly develop drug resistance, together with toxicity problems, requires the expansion of additional classes of antiviral drugs. Integrase is an attractive target for antivirals [2] [3] [4] because it is vital for HIV replication and, unlike protease and reverse transcriptase, there are no known counterparts in the host cell. Integrase catalyzes two reactions; 3Ј-end processing, in which two deoxynucleotides are removed from the 3Ј ends of the viral DNA and the strand transfer reaction, in which the processed 3Ј ends of the viral DNA are covalently ligated to the host chromosomal DNA. [5] [6] [7] Integration of the proviral DNA is a key step in allowing viral DNA to become permanently inserted into the host genome. This step is essential for the subsequent transcription of the viral genome which leads to production of new viral genomic RNA and viral proteins needed for the production of the next round of infectious virus. Essentially, furthermore, integrase uses a single active site to hold two different configurations of DNA substrates, which may restrict the ability of HIV to develop drug resistance to integrase inhibitors. Systematic screening of potential inhibitors has been undertaken using mostly purified integrase-based assays. From such screens several integrase inhibitor classes have now been identified. [8] [9] [10] [11] [12] One of them, Raltegravir (MK-0518) was recently shown to be active in patients thereby demonstrating the potential of anti-integrase agents. 13, 14) The tetrameric 4-hydroxycoumarin (NSC 158393, I) was first descripted against HIV-1 integrase (HIV-1 IN) by Mazumder et al. 15) with potent inhibition of both 3Ј-processing (IC 50 ϭ1.5 mM) and strand transfer (IC 50 ϭ0.8 mM). They also delineated the minimum active pharmacophore of NSC 158393 necessary for inhibitory activity, 16) i.e., a coumarin dimmer containing an aryl substituent on the central linker methylene (II). In previous papers, we have reported the synthesis of 4-hydroxycoumarin dimmers bearing aniline mustard moiety 17) and reasoned the mustard moiety might react with nearby nucleophile of the coumarin-IN complex binding site to form a covalent bonding and to improve the inhibitory activity. However, these compounds did not markedly increase the inhibitory activity and seemed to fail forming covalent binding at coumarin-IN complex binding site. We also reported biscoumarins with a diversified modification on the linker 18) and enabled us to know that the benzoyloxyphenyl linker (III) seemed important for the inhibitory activity. These encouraging results prompted us to modify these lead compounds. Further structural theoretical studies by Long et al. 19) on the binding site of HIV-1 IN allow establishing that the spatial distance between two adjacent active sites (one from each dimer) are very important for inhibitory activity. Thus, we postulate that compounds (7, 8, 12-14, 18) with the chain extension on the linker may be more beneficial to enhance the activity. Afterwards, according to the instability of ester bond on the benzoyloxyphenyl linker, we have replaced an amide bond instead, such as compound 4. With the aim to examine our assumption and find more potent new anti-HIV agents, in this paper we describe the synthesis and inhibitory activity of a series of novel bis-or tetracoumarins against HIV-1 IN.
Chemistry
The target compounds in this study were synthesized as shown in Charts 2-4. inhibitory activity in a 3Ј-processing assay which was performed as described previously. 20, 21) Effects against the strand transfer activity were evaluated during the same assay from the homologous integration events and found to be no significantly different from 3Ј-processing inhibition, thus confirming that coumarins affect equally both steps of the integration reaction. Table 1 lists the inhibitory activity of a series of bis-or tetra-coumarin analogues against the recombinant wild-type HIV-1 IN enzyme. The inhibitory activity of NSC 158393 (I) and (II) were included for a comparison. Among nine compounds in this series, three demonstrated potent activities with IC 50 less than 1.0 mM, two displayed activities less than 4.0 mM, two showed activities at 23.1 mM, and two showed weak activities with IC 50 larger than 90 mM, respectively. Compound 18, the tetra-coumarin with the longest extended linker was the most potent one in this series, with IC 50 of 0.49 mM. Compounds 14 and 16, with the bis-coumarin which linked with bis-benzoyl moiety instead of bis-coumarin like NSC 158393 (I), possessed IC 50 of 0.96 and 0.58 mM, respectively. It was of interesting that the existing of bis-benzoyl moiety in 14 and 16 seemed to serve important role on potency, because 12, only with bis-acetoxy moiety, and 7 or 8, with only mono-benzoyl moiety, showed a remarkable decreased activity. Further, compound 18 was more active than tetra-coumarin NSC 158393 (I). This is the first finding that the extended linker gained increased activity.
Conclusion
In summary, we have described the synthesis and HIV-IN inhibitory activity of novel bis-or tetra-coumarin analogues. The results showed that most of these analogues exhibited moderate or high activity against HIV-IN. The most active compound 18 exhibited about 2-fold more potent activity than lead NSC 158393 (I). This result confirmed our assumption that spatial distance between each coumarin unit and linker are very important for inhibitory activity. The introduction of an extended linker between two bis-coumarin might improve the inhibitory activity. As a result our studies provide useful indicators for guiding the further rational design of more potent new HIV-IN inhibitor.
Experimental
General Melting points (mp) were taken on a BUCHI 530 apparatus and are uncorrected. Merck Art No105554 plates precoated with Silica gel 60 containing fluorescent indicator were used for thin-layer chromatography, and Silica gel 60 (Merck Art No. 109385, 230-400 mesh) was employed for column chromatography. Evaporations were carried out at Ͻ50°C using a rotary evaporator at reduced pressure (water aspirator). 1 H-and 13 C-NMR spectra were obtained at Varian 300 NMR spectrometer at 300 and 75 MHz, respectively. Where necessary, deuterium exchange experiments were used to obtain proton shift assignments. Mass spectra were recorded on a JEOL J.M.S-300 spectrophotometer. Analytical samples were dried under reduced pressure at 78°C in the presence of P 2 O 5 for at least 12 h unless otherwise specified. Elemental analyses were obtained from Perkin-Elmer 2400 Elemental Analyzer.
General Procedure for Compounds 1, 2 and 17 To a solution of 4-carboxybenzaldehyde (6.9 mmol) and DCC (10.1 mmol) in CH 2 Cl 2 (50 ml) were added DMAP (1 mmol) and 6.9 mmol of 4-methoxyphenol, 4-methoxyaniline or 4-hydroxybenzaldehyde, respectively. The reaction mixture was stirred over night at room temperature. The mixture was filtered, and the solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel with n-hexane/EtOAc (9/1) and recrystallized from methanol. 
General Procedure for Compounds 5, 6, 9-11 and 15
To an ice cold solution of certain alcohols (6.5 mmol) in triethylamine (5 ml) and dry dichloromethane (20 ml) were added acetyl or benzoyl chloride (6.5 mmol), respectively. The mixture was stirred at room temperature for 6 h and then poured onto ice. The mixture was extracted with ethyl acetate three times. The organic layers washed with brine, dried under anhydrous magnesium sulfate. The filtrate was concentrated under vacuo. The residue was purified by flash chromatography on silica gel with n-hexane/EtOAc (5/1) and crystallized from n-hexane to afford the corresponding products 5, 6, 9-11 and 15.
2-(4-Formylphenoxy)ethyl Acetate (5): Yield: 0.87 g (64%), a white powder, mp 93-95°C. HIV-1 Integrase Inhibitory Assay. Oligonucleotides Oligonucleotides were purchased from Eurogentec and further purified on 18% acrylamide/ urea denaturing gel. U5B: GTGTGGAAAATCTCTAGCA; U5B-2: GTG-TGGAAAATCTCTAG; U5A: 5Ј-ACTGCTAGAGATTTTCCACAC; ST1: AGTGAATTAGCCCTTGGTCA-biotine; ST2: 5Ј-TGACCAAGGGCTAAT-TCACT-biotine; U5B and U5B-2 were radiolabeled using T4 polynucleotide kinase for respectively 3Ј-processing and strand transfer reactions.
HIV-1 Integrase Assays Wild-type HIV-1 integrase was purified as describsed previously. 15, 16) 3Ј-Processing assay was performed in a reaction volume of 20 ml containing 0.025 pmol of labeled U5A/U5B doublestranded DNA substrate and 1 pmol of integrase in buffer A [20 mM Hepes (pH 7.2), 10 mM MgCl 2 , 25 mM NaCl, 1 mM DTT]. Products were separated on a 18% acrylamide/urea denaturing gel and quantified on a phosphoimager using Image Quant software (Amersham Pharmacia Biotech). Strand transfer reactions were performed in triplicate in 96-well plates using 0.25 pmol of labeled U5A/U5B-2 double-stranded DNA substrate, 12 pmol of ST1/ST2 3Ј-biotinylated target DNA and 2 pmol of integrase in buffer A in a final volume of 40 ml. Radiolabeled reaction products were bound to Streptavidincoated magnetic beads (DynaL), washed twice in buffer B (PBS buffer supplemented with 0.025% tween 20 and 10 mg/ml BSA) and quantified on a beta radiation counter. Inhibition in the presence of drugs is expressed as the fractional product in percent of the control without drug.
